Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years: The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma Study.

Chest·2021
Same author

Giants in Chest Medicine: Donald C. Zavala, MD, FCCP.

Chest·2019
Same author

Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2019
Same author

Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies.

The European respiratory journal·2017
Same author

A four-dimensional computed tomography comparison of healthy and asthmatic human lungs.

Journal of biomechanics·2017
Same author

Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients.

The Journal of allergy and clinical immunology·2017

Related Experiment Video

Updated: Jul 11, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Immunotherapy of asthma using CpG oligodeoxynucleotides.

Joel N Kline1

  • 1Department of Medicine, Roy J. and Lucille A. Carver College of Medicine, Graduate Program in Immunology, C33GH UIHC, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA. joel-kline@uiowa.edu

Immunologic Research
|October 6, 2007
PubMed
Summary

The Hygiene Hypothesis suggests microbes protect against allergies. CpG oligodeoxynucleotides (ODN), mimicking bacterial DNA, show promise in preventing and treating atopic asthma, with clinical trials underway.

Related Experiment Videos

Last Updated: Jul 11, 2026

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Area of Science:

  • Immunology
  • Allergy Research
  • Microbiome Studies

Background:

  • Rising prevalence and severity of asthma and atopic disorders.
  • The
  • Hygiene Hypothesis
  • proposes microbial exposure reduces atopic disease risk.
  • Innate immune mechanisms likely mediate this protection.

Purpose of the Study:

  • Investigate CpG oligodeoxynucleotides (ODN) as a potential therapy for atopic disorders.
  • Explore the therapeutic potential of bacterial DNA-mimicking compounds.
  • Validate the use of CpG ODN for preventing and treating atopic asthma.

Main Methods:

  • Utilized CpG ODN, which mimic prokaryotic DNA motifs.
  • Studied the induction of Th1-type immune responses by CpG ODN.
  • Conducted preclinical studies in animal models of atopic asthma.

Main Results:

  • CpG ODN demonstrated efficacy in preventing and treating incipient and established atopic asthma in animal models.
  • CpG ODN effectively induced anti-atopic immune responses.
  • Preclinical findings support the therapeutic hypothesis.

Conclusions:

  • CpG ODN represent a novel therapeutic strategy for atopic diseases.
  • The findings support the translation of CpG ODN immunotherapy into clinical trials.
  • Further research is ongoing to explore CpG ODN's role in immunotherapy for atopic conditions.